The Move to Bundled Payments Will Be Paradigm-Changing
As with any legislation, there are both positive and negative aspects. Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease.
Bruce Minsky, MD
It is difficult to comment on the full impact of the Affordable Care Act (ACA), since it is complex and how each provision will impact each component of health care is still not fully understood. As with any legislation, there are both positive and negative aspects.
Specific to oncology, one of the greatest impacts of the ACA will be the move to a bundled payment for a treatment of a disease. This will refocus the question in multidisciplinary tumor boards from “what is the ideal way to stage, treat, and manage the patient” to “what is the ideal way to stage, treat, and manage the patient within the reimbursement envelope for their disease.” The ultimate impact of these 7 paradigm-changing words remains to be determined.
More on the Supreme Court Decision
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
